How this cancer immunotherapy pioneer is working to improve next-gen drugs
If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies.
As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells.
Checkpoint inhibitors, so-called… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. ... Biopharmaceuticals, Oncology, FDA Bristol-Myers Squibb, Opdivo, Yervoy, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2017 Category: Pharmaceuticals Source Type: news
Bristol won't seek faster Opdivo/Yervoy lung cancer approval
(Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Bristol won't seek faster Opdivo, Yervoy lung cancer drug approvals
(Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
SWOG to conduct immunotherapy clinical trial to treat rare cancers
SWOG, a part of National Cancer Institute ’s National Clinical Trials Network and the NCI Community Oncology Research Programme, has launched the DART immunotherapy trial of ipilimumab and nivolumab (Opdivo) to treat rare cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - January 19, 2017 Category: Pharmaceuticals Source Type: news
Cancer immunotherapy drugs may have cardiac side effects
Ryan MaassNASHVILLE, Nov. 3 (UPI) -- Two cancer immunotherapy drugs, ipilimumab and nivolumab, may cause rare and sometimes fatal cardiac side effects, Vanderbilt University researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 3, 2016 Category: Consumer Health News Source Type: news
Fatal Myocarditis -- Rare New ADR With Immunotherapy Fatal Myocarditis -- Rare New ADR With Immunotherapy
Fatal myocarditis has been reported in melanoma patients treated with ipilimumab and nivolumab; this appears to be a rare T-cell-driven reaction.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Two Ipilimumab Trials Show Survival Benefit, and More Toxicity Two Ipilimumab Trials Show Survival Benefit, and More Toxicity
Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Melanoma tumors use interferon-gamma mutations to fight immunotherapy
Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers report. These findings open the door to testing an array of IFN-y genes prospectively as a predictor for response to ipilimumab and for exploring new combinations to defeat IFN-y-related resistance. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 22, 2016 Category: Science Source Type: news
Yervoy Plus Chemo Disappoints in SCLC (CME/CE)
(MedPage Today) -- Combo treatment did not prolong survival versus chemo alone in extensive-stage disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2016 Category: Hematology Source Type: news
Deals this week: AbbVie, Evolva, Trek Therapeutics
AbbVie has entered a clinical trial agreement with Bristol-Myers Squibb Company to evaluate the safety and efficacy of the former ’s Rova-T, as well as in combination with the latter’s Opdivo, along with Opdivo + Yervoy regimen as a treatment for rela… (Source: Drug Development Technology)
Source: Drug Development Technology - July 28, 2016 Category: Pharmaceuticals Source Type: news
Combining Ipilimumab with local treatments improved survival for patients with melanoma
Among patients with melanoma, those who received both ipilimumab (Yervoy) and local peripheral treatments such as radiotherapy or electrochemotherapy had significantly prolonged overall survival compared with those who received only ipilimumab, according to a retrospective clinical study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2016 Category: Science Source Type: news
Combining Ipilimumab with local treatments improved survival for patients with melanoma
( < i > American Association for Cancer Research < /i > ) Among patients with melanoma, those who received both ipilimumab (Yervoy) and local peripheral treatments such as radiotherapy or electrochemotherapy had significantly prolonged overall survival compared with those who received only ipilimumab, according to a retrospective clinical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2016 Category: Cancer & Oncology Source Type: news
AbbVie and Bristol-Myers to conduct combination trial of Rova-T plus Opdivo and Opdivo + Yervoy regimen
AbbVie and Bristol-Myers Squibb will jointly conduct a Phase I/II clinical trial of Rova-T (rovalpituuzumab tesirine) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen to treat relapsed extensive-stage, small-cell lung c … (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2016 Category: Pharmaceuticals Source Type: news
Pembrolizumab-ipilimumab combo is highly active in advanced melanoma
CHICAGO – The combination of pembrolizumab, an antibody to the human cell surface receptor programmed death-1 (PD-1), and ipilimumab, an antibody to the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), is highly active against advanced melanoma and has acceptable safety,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 16, 2016 Category: Dermatology Source Type: news
